320 related articles for article (PubMed ID: 20509341)
1. Study of rifampicin resistance and comparison of dapsone resistance of M. leprae in pre- and post-MDT era.
Gupta UD; Katoch K; Katoch VM
Indian J Lepr; 2009; 81(3):131-4. PubMed ID: 20509341
[TBL] [Abstract][Full Text] [Related]
2. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
3. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
4. Drug susceptibility of Mycobacterium leprae: a retrospective analysis of mouse footpad inoculation results from 1983 to 1997.
Sekar B; Elangeswaran N; Jayarama E; Rajendran M; Kumar SS; Vijayaraghavan R; Anandan D; Arunagiri K
Lepr Rev; 2002 Sep; 73(3):239-44. PubMed ID: 12449888
[TBL] [Abstract][Full Text] [Related]
5. Does dapsone resistance really matter in the MDT era?
Ji B
Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):54-5. PubMed ID: 11480322
[No Abstract] [Full Text] [Related]
6. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines.
Matsuoka M; Budiawan T; Aye KS; Kyaw K; Tan EV; Cruz ED; Gelber R; Saunderson P; Balagon V; Pannikar V
Lepr Rev; 2007 Dec; 78(4):343-52. PubMed ID: 18309708
[TBL] [Abstract][Full Text] [Related]
7. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
[TBL] [Abstract][Full Text] [Related]
9. Primary dapsone resistance in Cebu, The Philippines; cause for concern.
dela Cruz E; Cellona RV; Balagon MV; Villahermosa LG; Fajardo TT; Abalos RM; Tan EV; Walsh GP
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):253-6. PubMed ID: 8862258
[TBL] [Abstract][Full Text] [Related]
10. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Matsuoka M; Kashiwabara Y; Namisato M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
Dhople AM; Lamoureux LC; Gardner GD
Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance in leprosy: lessons from past and future perspective.
Gupta UD; Katoch VM
Indian J Lepr; 1999; 71(4):451-63. PubMed ID: 10804973
[TBL] [Abstract][Full Text] [Related]
13. In vitro resistance test of human leprosy bacilli to anti-leprous drugs.
Ishihara S; Hagiwara S; Fujuda T
Microbios; 1977; 19(76):117-23. PubMed ID: 366337
[TBL] [Abstract][Full Text] [Related]
14. Multidrug therapy (MDT) and leprosy control.
Noordeen SK
Indian J Lepr; 1990; 62(4):448-58. PubMed ID: 2086680
[No Abstract] [Full Text] [Related]
15. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy.
Cambau E; Carthagena L; Chauffour A; Ji B; Jarlier V
Clin Infect Dis; 2006 Jan; 42(2):238-41. PubMed ID: 16355335
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo experiments with the new inhibitor of mycobacterium leprae brodimoprim alone and in combination with dapsone.
Seydel JK; Wempe EG; Rosenfeld M; Jagannathan R; Mahadevan PR; Dhople AM
Arzneimittelforschung; 1990 Jan; 40(1):69-75. PubMed ID: 2187440
[TBL] [Abstract][Full Text] [Related]
18. Possible mode of emergence for drug-resistant leprosy is revealed by an analysis of samples from Mexico.
Matsuoka M; Suzuki Y; Garcia IE; Fafutis-Morris M; Vargas-González A; Carreño-Martinez C; Fukushima Y; Nakajima C
Jpn J Infect Dis; 2010 Nov; 63(6):412-6. PubMed ID: 21099091
[TBL] [Abstract][Full Text] [Related]
19. Study of multidrug therapy in paucibacillary leprosy.
Kar PK; Sohi AS
J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
[TBL] [Abstract][Full Text] [Related]
20. Concepts behind the development of multiple drug therapy regimens in leprosy.
Waters MF
Lepr Rev; 1986 Dec; 57 Suppl 1():61-7. PubMed ID: 3295437
[No Abstract] [Full Text] [Related]
[Next] [New Search]
